ArticleBMC gastroenterology2025
Pan-immune-inflammation value and mortality in the US adult MASLD: a nonlinear NHANES analysis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Predictive Value of the Pan-Immune-Inflammation Value for Atrial Fibrillation Risk in Patients with Coronary Artery Disease: A Multicenter Machine Learning Study.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
BACKGROUND AND
aimSystemic inflammatory markers derived from immune cell counts have been associated with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD). However, the clinical relevance of the pan-immune-inflammation value (PIV), a composite index incorporating neutrophil, platelet, monocyte, and lymphocyte counts, in relation to mortality has not been fully elucidated. This study aimed to evaluate the association between PIV and both all-cause and cardiovascular mortality in individuals with MASLD.
methodsIn this population-based cohort study, 15,471 participants with MASLD were identified from the 1999-2018 National Health and Nutrition Examination Survey (NHANES). Baseline demographic characteristics, including age, sex, and ethnicity, were collected. Multivariate Cox proportional hazards models and restricted cubic spline analyses were employed to examine the associations between PIV and mortality outcomes.
resultsIn fully adjusted models, log-transformed PIV (LnPIV) was independently associated with higher risks of all-cause (hazard ratio [HR] 1.26; 95% confidence interval [CI], 1.14-1.38) and cardiovascular mortality (HR 1.31; 95% CI, 1.10-1.56). Notably, a U-shaped nonlinear association was observed between PIV and all-cause mortality, while a J-shaped relationship was found for cardiovascular mortality. These associations were more pronounced among individuals with a poverty-income ratio (PIR) < 1, suggesting increased vulnerability in socioeconomically disadvantaged populations.
conclusionPIV may be a biomarker associated with increased mortality risk in individuals with MASLD, particularly among those from lower socioeconomic backgrounds. These findings underscore the association between PIV and mortality risk and highlight the need for further prospective validation to evaluate its potential role in risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.